Our top pick for
Beginners
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy DocuSign stock | $225.73
Own DocuSign stock in just a few minutes.
Fact checked
DocuSign, Inc is a software-application business based in the US. DocuSign shares (DOCU) are listed on the NASDAQ and all prices are listed in US Dollars. DocuSign employs 3,909 staff and has a trailing 12-month revenue of around USD$1.3 billion.
How to buy shares in DocuSign
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for DocuSign. Find the stock by name or ticker symbol: DOCU. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until DocuSign reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of USD$225.73, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of DocuSign, depending on your broker.
- Check in on your investment. Congratulations, you own a part of DocuSign. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
DocuSign share price
Use our graph to track the performance of DOCU stocks over time.DocuSign shares at a glance
Information last updated 2021-03-03.
| Latest market close | USD$225.73 |
|---|---|
| 52-week range | USD$64.88 - USD$275.46 |
| 50-day moving average | USD$247.1818 |
| 200-day moving average | USD$227.7718 |
| Wall St. target price | USD$278.41 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-1.366 |
Buy DocuSign shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy DocuSign stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
DocuSign price performance over time
Historical closes compared with the close of $225.73 from 2021-02-25
| 1 week (2021-02-26) | -0.41% |
|---|---|
| 1 month (2021-02-05) | -9.84% |
| 3 months (2020-12-07) | -2.92% |
| 6 months (2020-09-04) | 4.38% |
| 1 year (2020-03-06) | 168.66% |
|---|---|
| 2 years (2019-03-07) | 306.72% |
| 3 years (2018-03-04) | N/A |
| 5 years (2016-03-04) | N/A |
Is DocuSign under- or over-valued?
Valuing DocuSign stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DocuSign's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DocuSign's PEG ratio
DocuSign's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.6429. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DocuSign's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DocuSign financials
| Revenue TTM | USD$1.3 billion |
|---|---|
| Gross profit TTM | USD$733.3 million |
| Return on assets TTM | -6.23% |
| Return on equity TTM | -43.85% |
| Profit margin | -16.83% |
| Book value | $2.284 |
| Market capitalisation | USD$44.5 billion |
TTM: trailing 12 months
Shorting DocuSign shares
There are currently 3.5 million DocuSign shares held short by investors – that's known as DocuSign's "short interest". This figure is 16.5% down from 4.2 million last month.
There are a few different ways that this level of interest in shorting DocuSign shares can be evaluated.
DocuSign's "short interest ratio" (SIR)
DocuSign's "short interest ratio" (SIR) is the quantity of DocuSign shares currently shorted divided by the average quantity of DocuSign shares traded daily (recently around 2.8 million). DocuSign's SIR currently stands at 1.25. In other words for every 100,000 DocuSign shares traded daily on the market, roughly 1250 shares are currently held short.
However DocuSign's short interest can also be evaluated against the total number of DocuSign shares, or, against the total number of tradable DocuSign shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DocuSign's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 DocuSign shares in existence, roughly 20 shares are currently held short) or 0.0218% of the tradable shares (for every 100,000 tradable DocuSign shares, roughly 22 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against DocuSign.
Find out more about how you can short DocuSign stock.
DocuSign share dividends
We're not expecting DocuSign to pay a dividend over the next 12 months.
DocuSign share price volatility
Over the last 12 months, DocuSign's shares have ranged in value from as little as $64.88 up to $275.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DocuSign's is 0.8726. This would suggest that DocuSign's shares are less volatile than average (for this exchange).
DocuSign overview
DocuSign, Inc. provides cloud based software in the United States and internationally. The company provides e-signature solution that enables businesses to digitally prepare, execute, and act on agreements. It also offers DocuSign CLM, which automates workflows across the entire agreement process; Intelligent Insights that use artificial intelligence to search and analyze agreements by legal concepts and clauses; Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce; and Negotiate for Salesforce that supports for approvals, document comparisons, and version control. In addition, the company provides Guided Forms, which enable complex forms to be filled via an interactive and step-by-step process; Click that supports no-signature-required agreements for standard terms and consents; Identify, a signer-identification option for checking government-issued IDs; Standards-Based Signatures, which support signatures that involve digital certificates; Payments that enables customers to collect signatures and payment; and eNotary, which offers the ability to execute electronic notarial acts. Further, it offers industry-specific cloud offerings, including Rooms for Real Estate that provides a way for brokers and agents to manage the entire real estate transaction digitally; Rooms for Mortgage, which offers digital workspace to create and close mortgages; FedRAMP, an authorized version of DocuSign eSignature for U.S. federal government agencies; and life sciences modules that support compliance with the electronic signature practices. The company sells its products through direct, partner-assisted, and Web-based sales. It serves enterprise, commercial, and small businesses, such as professionals, sole proprietorships, and individuals. The company was founded in 2003 and is headquartered in San Francisco, California.
Frequently asked questions
More guides on Finder
-
How to buy Achilles Therapeutics plc (ACHL) stock when it goes public
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
-
How to buy SEMrush Holdings Inc (SEMR) stock when it goes public
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
-
How to buy ChargePoint (DOCU.US) stock when it goes public
Everything we know about the ChargePoint IPO, plus information on how to buy in.
-
How to buy Kaltura Inc (KLTR) stock when it goes public
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
-
How to buy Rocket Lab (DOCU.US) stock when it goes public
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
-
How to buy Soho House (DOCU.US) stock when it goes public
Everything we know about the Soho House IPO, plus information on how to buy in.
-
How to buy VIZIO (VZIO) stock when it goes public
Everything we know about the VIZIO IPO, plus information on how to buy in.
-
How to buy IDW Media Holdings Inc (IDW) stock when it goes public
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
-
How to buy Karooooo Ltd (KARO) stock when it goes public
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
-
How to buy Connect Biopharma Holdings Limited (CNTB) stock when it goes public
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
Ask an Expert